A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma

Trial Details

NCT ID
NCT07579234
Phase
PHASE3
Sponsor
Shandong New Time Pharmaceutical Co., LTD
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • F182112 single-agent
  • Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
Locations (sample)
  • Tianjing, China|31.46583,120.77196

Key Eligibility Criteria

  • Patients must meet all of the following inclusion criteria to be eligible for enrollment in this study:
  • Provide informed consent and voluntarily sign the informed consent form; Be male or female, aged ≥18 years;
  • Have relapsed or refractory multiple myeloma (RRMM) who have previously failed therapy with regimens containing at least one agent from each of the…
  • Before randomization, the investigator must pre-select a standard of care (SOC) treatment regimen based on the patient's disease status;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →